ASGR2

Across TCGA pan-cancer cohorts, ASGR2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ASGR2 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ASGR2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ASGR2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where ASGR2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.517	0.235	.016	6	view →
LUAD	OS	Tertile	III,IV	0.270	0.784	.008	6	view →
LSCC	OS	Median	All	0.771	1.000	.015	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ASGR2–PDAC (DFS)

Open the PDAC breakdown →